## PATENT ASSIGNMENT

# Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE: NEW ASSIGNMENT

NATURE OF CONVEYANCE: ASSIGNMENT

## **CONVEYING PARTY DATA**

Name	Execution Date
Steward St. Elizabeth's Medical Center of Boston, Inc.	07/17/2012

## **RECEIVING PARTY DATA**

Name:	Steward Research and Specialty Projects Corporation
Street Address:	500 Boylston Street
City:	Boston
State/Country:	MASSACHUSETTS
Postal Code:	02116

## PROPERTY NUMBERS Total: 51

Property Type	Number
Patent Number:	5830879
Patent Number:	6121246
Patent Number:	5652225
Patent Number:	5980887
Patent Number:	5858990
Patent Number:	6258787
Patent Number:	5990092
Patent Number:	6133231
Patent Number:	6063805
Patent Number:	6011054
Patent Number:	6369039
Patent Number:	6569428
Patent Number:	6676937
Patent Number:	7368420
Patent Number:	7125856
	PATENT

PATENT "

REEL: 028801 FRAME: 0100

Patent Number:	6239162
Patent Number:	6689807
Patent Number:	6353015
Patent Number:	6562858
Patent Number:	8075880
Patent Number:	6849654
Patent Number:	7122007
Patent Number:	7638273
Application Number:	09961128
Application Number:	09970088
Application Number:	10278759
Application Number:	10530038
Application Number:	10633407
Application Number:	10696391
Application Number:	11254524
Application Number:	11321143
Application Number:	11339808
Application Number:	11412416
Application Number:	11630888
Application Number:	11887016
Application Number:	11887021
Application Number:	11920091
Application Number:	11997484
Application Number:	12090046
Application Number:	12090706
Application Number:	12090726
Application Number:	12090744
Application Number:	12091405
Application Number:	12294081
Application Number:	12312932
Application Number:	12447091
Application Number:	12447114
Application Number:	12495417
Application Number:	12513017
Application Number:	12677393
	PATENT '

#### **CORRESPONDENCE DATA**

**Fax Number**: 6172274420 **Phone**: 6172390100

Email: kdrury@edwardswildman.com

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

via US Mail.

Correspondent Name: Edwards Wildman Palmer LLP

Address Line 1: P.O. Box 55874

Address Line 4: Boston, MASSACHUSETTS 02205

ATTORNEY DOCKET NUMBER: 304776/0112

NAME OF SUBMITTER: Elbert Chiang, Ph.D.

Total Attachments: 9

source=71417.Assignment#page1.tif

source=71417.Assignment#page2.tif

source=71417.Assignment#page3.tif

source=71417.Assignment#page4.tif

source=71417.Assignment#page5.tif

source=71417.Assignment#page6.tif

source=71417.Assignment#page7.tif

source=71417.Assignment#page8.tif

source=71417.Assignment#page9.tif

### ASSIGNMENT

THIS ASSIGNMENT, made this 17 day of July, 2012, by Steward St. Elizabeth's Medical Center of Boston, Inc., (hereinafter referred to as Assignor), having its principal place of business at 500 Boylston St, Boston, MA 02116.

WHEREAS, Assignor has ownership, by assignment, of the Patent Applications listed in Schedule A and Schedule B; and

WHEREAS, Steward Research and Specialty Projects Corporation, having its principal place of business at 500 Boylston St, Boston, MA 02116, (hereinafter referred to as Assignee), is desirous of acquiring the entire right, title and interest in, to and under said Patent Application and the invention covered thereby;

NOW, THEREFORE, in consideration of good and valuable consideration, receipt of which is hereby acknowledged, the said Assignor has sold, assigned, transferred and set over, and does hereby sell, assign, transfer and set over to the said Assignee, the entire right, title and interest for the United States of America and all other countries in and to said applications for all original, divisional, continuation, continuation-in-part, substitute or reissue applications and patents applied for or granted therefore in the United States of America and all other countries on the attached list of Schedule A and Schedule B, and the Commissioner of Patents and Trademarks is hereby authorized and requested to issue all patents on Schedule A to said assignee herein, as assignee of the entire interest therein; and the undersigned for itself and its legal representatives, heirs and assigns does hereby agree and covenant without further remuneration, to execute and deliver all divisional, continuation, continuation-in-part, reissue and other applications for Letters Patent and all assignments thereof to said assignee or its assigns, to communicate to said assignee or its representatives all facts known to the undersigned respecting said invention listed on Schedule A and Schedule B whenever requested, to testify in any interferences or other legal proceedings in which said application or patent may become involved, to sign all lawful papers, make all rightful oaths, and do generally everything necessary to aid assignee, its successors, assigns and nominees to obtain patent protection for said invention listed on Schedule A and Schedule B in the United States of America and all other countries, the expenses incident to said application listed on Schedule A and *Schedule B* to be borne and paid by said assignee.

1

America 4434764.1

AND Assignor hereby grant the following individuals the power to insert on this Assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document:

## EDWARDS WILDMAN PALMER LLP

All practitioners at Customer Number 21874

AND Assignor acknowledges an obligation of assignment of this invention to Assignee at the time the invention was made.

America 4434764.1

2

	Signed for and on behalf of
	Steward St. Elizabeth Medical Center of Boston, Inc.
	Millabel
	Joseph C. Maher Jr Esq. Altorney and Authorised Official
Date: <u>7/17/17</u>	
United States of America State of <u>MassachuseH</u> County of <u>Suffolk</u>	) <u>5</u> ) ss.: )
	1012 , before me 1017 , before me hown to be the individual poing instrument, and acknowledged execution
of the same.	Jaia E. Rau
	Notary Public
	SARA E, RAU Notary Public COMMONWEALTH OF MASSACHUSET My Commission Expires August 3, 2018
	and the same with the same to the same of

## SCHEDULE A

US	US Patent No. or	Title	Till D. t.	Y 12-1
Application	Publication No.	<u>1100</u>	Filling Date	Issue Date or
No.	Funication (vo.			Publication Date
08/538,301	5,830,879	Treatment of pecular fainer union was rules as faithful assemble fair (MECE)	10/2/1995	*********
08/545,998	6,121,246	Treatment of vascular injury using vascular endothelial growth factor (VEGF)  Method for treating ischemic tissue		11/3/1998
08/675,523	5,652,225	Methods and products for nucleic acid delivery	10/20/1995	9/19/2000
08/744,882	5,980,887	Methods for enhancing angiogenesis with endothelial progenitor cells	7/3/1996	7/29/1997
08/810,453	5,858,990	Fas ligand compositions for treatment of proliferative disorders	11/8/1996	11/9/1999
08/910,539	6,258,787	Treatment of vascular injury	3/4/1997	1/12/1999
08/927,394	5,990,092		7/30/1997	7/10/2001
09/086,498		GATA-6 transcription factor; compositions and methods	8/27/1997	11/23/1999
	6,133,231	Angiogenesis using hepatocyte growth factor	5/22/1998	10/17/2000
09/185,562	6,063,805	Method for treating hypertension	11/4/1998	5/16/2000
09/187,466	6,011,054	Method for treating depression, obsessive compulsive disorder, and anxiety with N- acetyl serotonin	11/4/1998	1/4/2000
09/204,254	6,369,039	High efficiency local drug delivery	12/3/1998	4/9/2002
09/228,020	6,569,428	Pharmaceutical products comprising endothelial cell precursors	1/11/1999	5/27/2003
09/265,041	6,676,937	Compositions and methods for modulating vascularization	3/9/1999	1/13/2004
09/408,905	7,368,420	AKT Compositions for Enhancing Survival of Cells	9/29/1999	5/6/2008
09/546.733	7,125,856	Angiogenic growth factors for treatment of peripheral neuropathy	4/11/2000	10/24/2006
09/559,609	6,239,162	Method for treating depression	4/27/2000	5/29/2001
09/590,740	6,689,807	HMG CoA reductase inhibitors for promoting angiogenesis	6/8/2000	2/10/2004
09/673,451	6,353,015	Method of treating neurodegenerative disorders	3/23/2001	3/5/2002
09/834,041	6,562,858	Method for treating depression	4/12/2001	5/13/2002
09/961,128	US20020155421	Endothelial cell mitogen bjoassay	9/21/2001	10/24/2002
09/970,088	US20020151489	Use of lymphangiogenic agents to treat lymphatic disorders	10/2/2001	10/17/2002
10/278,759	US20030114382	Glycogen synthase kinase function in endothelial cells	10/23/2002	6/19/2003
10/390,559	8,075,880	Compositions and methods for regulating angiogenesis	3/17/2003	12/13/2011
10/390,967	6,849,654	5-methoxy-carbonylamino-N-acetyltryptamine compounds and derivatives thereof	3/18/2003	2/1/2005
10/436,548	7,122,007	Methods of and systems and devices for assessing intracranial pressure noninvasively	5/12/2003	10/17/2006
10/530,038	US20060167021	Inhibition of see for treatment of reperfusion injury related to revascularization	10/3/2003	7/27/2006
10/633,407	US20040105860	Cell modulation using a cytoskeletal protein	8/1/2003	6/3/2004
10/696,391	US20040228834	Compositions and methods for modulating vascularization	10/28/2003	11/18/2004
11/254,524	US20060105950	Morphogen compositions and use thereof to treat wounds	10/20/2005	
11/321,143	US20060194776	Compositions and methods for treating tissue ischemia	12/28/2005	5/18/2006
11/339,808	US20070173471	Morphogen compositions and methods of use thereof to treat heart disorders	1/24/2006	8/31/2006 7/26/2007

4

America 4434764.)

<u>US</u>	US Patent No. or	Title	Filing Date	Issue Date or
Application	Publication No.			Publication Date
No.				
11/412,416	US20070253937	Novel multipotent stem cells and use thereof	4/26/2006	11/1/2007
11/582,872	7,638,273	Generation and use of vasculogenic tumors and products derived from same	10/18/2006	12/29/2009
11/630,888	US20080200557	Method for Inhibiting Lipid Peroxidation	7/7/2005	8/21/2008
11/800,113	7,704,946	Reversible inhibition of pyramidal gap junction activity	5/3/2007	4/27/2010
11/887,016	US20090142753	Compositions and methods for detecting compounds to treat a neurological disorder	3/17/2006	6/4/2009
11/887,021	US20100028312	Stably transformed bone marrow-derived cells and uses thereof	3/24/2006	2/4/2010
11/920,091	US20100047776	Cell-Based Screening Assay for Compounds that Regulate the Expression of a Tumor	5/8/2006	2/25/2010
		Marker DJ-1	•	
11/997,484	US20080234385	Methods for Inhibiting TNP-alpha	7/26/2006	9/25/2008
12/090,046	US20090221683	Combination of CXCR4 Antagonist and Morphogen to Increase Angiogenesis	10/18/2006	9/3/2009
12/090,706	US20090155220	Use of Bone-Marrow Derived Stem Cells to Treat Ischemia	10/20/2006	6/18/2009
12/090,726	US20090325911	Use of Androgens for the Treatment of Parkinson's Disease	10/20/2006	12/31/2009
12/090,744	US20090023794	Use of Sumoylation Inhibitors for the Treatment of Neurodegenerative Disease	10/20/2006	1/22/2009
12/091,405	US20120014879	Use of Tumor Necrosis Pactor-alpha Receptor p75 for Treatment of Isehemia-Induced	10/24/2006	1/19/2012
		Neovascularization		
12/294,081	US20090105148	Compositions and Methods for Treating Myocardial Infaction	3/23/2007	4/23/2009
12/312,932	US20100003190	Method for Protecting Renal Tubular Epithelial cells from Radiocontrast Nephropathy	12/7/2007	1/7/2010
		(RCN)		
12/447,091	US20100135970	Methods for Reprogramming Adult Somatic Cells and Uses Thereof	10/26/2007	6/3/2010
12/447,114	US20100130414	Methods of Using E2F2 for the Treatment of Hypertension	10/29/2007	5/27/2010
12/495,417	US20100162419	Tumor Initiating Cells and Methods of Use	6/30/2009	6/24/2010
12/513,017	US20100150841	Use of Tumor Necrosis Factor Alpha P75 Receptor for the Reduction of Inflammation	10/31/2007	6/17/2010
12/677,393	US20110059537	Method of estimating risk of acute kidney injury	9/18/2008	3/10/2011

America 4434764.1

# SCHEDULE B

Country	Publication,	Title	Publication Date,
	Application, or	<del></del>	Filing Date,
	Patent No.		or Issue Date
Austria	AT298259	High Efficiency local drug delivery	7/15/2005
Australia	AU774542	High eddiciency local drug delivery	7/1/2004
Australia	AU1930800	High Efficiency local drug delivery	6/19/2000
Canada	CA2353602	Device for locally delivering a drug in a body cavity	6/8/2000
Germany	DE69925936	High efficiency local drug delivery	5/11/2006
Europe	EP1140273	Device for locally delivering a drug in a body cavity	10/10/2001
Japan	JP2003521275	High Efficiency local drug delivery	7/15/2003
PCT	WO0032267	High Efficiency local drug delivery	6/8/2000
Australia	AU7254896	Improved angiogenesis using hepatocyte growth factor	4/28/1997
PCT	WO9712629	Angiogenesis using hepatocyte growth factor	4/10/1997
Austria	AT347910	Method for treating ischemic tissue	1/15/2009
Austria	AT419014	Method for treating ischemic tissue	1/15/2009
Australia	AU725290	Method for treating ischemic tissue	10/12/2000
Australia	AU7454896	Method for treating ischemic tissue	5/7/1997
Canada	CA2235372	Method for treating ischemic tissue	4/24/2019
Germany	DE69636764	Method for treating ischemic tissue	4/24/1997
Europe	EP0883343	Compositions for treating ischemic tissue	12/16/1998
France	EP0883343	Compositions for treating ischemic tissue	12/16/1998
Great Britain	EP0883343	Compositions for treating ischemic tissue	12/16/1998
Italy	EP0883343	Compositions for treating ischemic tissue	12/16/1998
Netherlands	EP0883343	Method for treating ischemic tissue	12/16/1998
Europe	EP1625858	Compositions for treating ischemic tissue	2/15/2006
France	EP1625858	Compositions for treating ischemic tissue	12/31/2008
Great Britain	EP1625858	Compositions for treating ischemic tissue	12/31/2008
Germany	EP1625858	Compositions for treating ischemic tissue	12/31/2008
Japan	JP11514366	Method for treating ischemic tissue	12/71999
Japan	JP 9-516039	Method for treating ischemic tissue	10/18/1996
Japan	JP2008024718	Method for treating ischemic tissue	2/7/2008
Japan	JP2011174322	Method for treating ischemic tissue	10/18/1996
PCT	WO9714307	Method for treating ischemic tissue	4/24/1997
Australia	AU766238	Compositions and methods for modulating vascularization	10/9/2003
Australia	AU3073799	Compositions and methods for modulating vascularization	9/27/1999

6

America 4434764.1

Country	Publication,	Title	Publication Date,
	Application, or		Filing Date,
	Patent No.		or Issue Date
Canada	CA2322559	Compositions and methods for modulating vascularization	9/16/1999
Europe	EP1061800	Compositions and methods for modulating vascularization	12/27/2000
Japan	JP2010-157554	GM-CSF induced BPC mobilization	3/9/1999
Japan	JP2002506008	Compositions and methods for modulating vascularization	2/26/2002
Japan	JP2010265301	Compositions and methods for modulating vascularization	11/25/2010
PCT	WO9945775	Compositions and methods for modulating vascularization	9/16/1999
Australia	AU5243298	Methods for regulating angiogenesis	5/29/1998
Australia	AU743267	Methods for regulating angiogenesis	5/9/2002
Canada	CA2271690	Methods for regulating angiogenesis	5/14/1998
Germany	DE69738495	Methods for regulating angiogenesis	8/28/2008
Europe	EP0941125	Methods for regulating angiogenesis	9/15/1999
France	EP0941125	Methods for regulating angiogenesis	1/30/2008
Great Britain	EP0941125	Methods for regulating angiogenesis	1/30/2008
Germany	EP0941125	Methods for regulating angiogenesis	1/30/2008
Italy	EP0941125	Methods for regulating angiogenesis	1/30/2008
Europe	EP1618898	Methods for regulating angiogenesis	1/25/2006
Hong Kong	HK1023278	Methods for regulating anglogenesis	8/22/2008
Hong Kong	HK1082209	Methods for regulating angiogenesis	6/2/2006
Japan	JP2009-138858	Methods for regulating angiogenesis	11/6/1997
Japan	JP2001503427	Methods for regulating angiogenesis	3/13/2001
Japan	JP4628504	Methods for regulating anglogenesis	11/19/2010
Japan	JP2009197028	Methods for regulating angiogenesis	2/9/2011
PCT	WO9819712	Methods for regulating angiogenesis	9/3/2009
Austria	AT361669	Treatment of vascular injury	5/14/1998
Australia	AU725499	Treatment of vascular injury	6/15/2007.
Australia	AU7386196	Treatment of vascular injury	4/28/1997
Canada	CA2233499	Treatment of vascular injury	4/10/1997
Germany	DE69637075	Treatment of vascular injury	1/24/2008
Енгоре	EP0853450	Compositions for the treatment of vascular injury	7/22/1998
Japan	JP2000505780	Treatment of vascular injury	5/16/2000
Japan	JP2007181722	Treatment of vascular injury	7/19/2007
PCT	WO9712519	Treatment if vascular injury	4/10/1997
Canada	CA2523667	Methods of and systems and devices for assessing intracranial pressure non-invasively	11/25/2004
PCT	WO2004100770	Methods of and systems and devices for assessing intracranial pressure non-invasively	11/25/2004

America 4434764.1

<u>Country</u>	Publication,	Title	Publication Date,
	Application, or		Filing Date.
	Patent No.		or Issue Date
PCT	WO2007047718	Generation and use of vasculogenic tumors and products derived from same	4/26/2007
Australia	AU6760298	Method for treating hypertension	10/30/1998
PCT	WO9844796	Method for treating hupertension	10/15/1998
Australia	AU6880498	Method for treating depression, obsessive compulsive disoprder or anxiety	10/30/1998
PCT	WO9844924	Method for treating depression, obsessive compulsive disoprder or anxiety	10/15/1998
Australia	AU5787999	Method for treating neurodegenerative disorders	3/21/2000
PCT	WO0012045	Method for treatingneurodegenerative disorders	3/9/2000
Australia	AU742898	Fas ligand compositions for treatment of proliferative disorders	1/17/2002
Australia	AU6340398	Fas ligand compositions for treatment of proliferative disorders	9/22/1998
_Canada	CA2283459	Fas ligand compositions for treatment of proliferative disorders	9/11/1998
Europe	EP0981536	Fas ligand compositions for treatment of proliferative disorders	3/1/2000
PCT	WO9839354	Fas ligand compositions for treatment of proliferative disorders	9/11/1998
Australia	AU7525601	HMG COA reductase inhibitors for promoting angiogenesis	12/17/2001
Canada	CA2411396	HMG COA reductase inhibitors for promoting angiogenesis	12/13/2001
Europe	EP1286702	HMG COA reductase inhibitors for promoting angiogenesis	3/5/2003
PCT	WO0193608	HMO COA reductase inhibitors for promoting angiogenesis	12/13/2001
Australia	AU4083997	Gata-6 transcription factor; compositions and methods	3/26/1998
Canada	CA2264485	Gata-6 transcription factor: compositions and methods	3/12/1998
PCT	WO98710090	Gata-6 transcription factor; compositions and methods	3/12/1998
Australia	AU782819	Angiogenic growth factors for treatment of peripheral neuropathy	9/1/2005
Australia	AU4342700	Angiogenic growth factors for treatment of peripheral neuropathy	11/2/2000
Canada	CA2365434	Augiogenic growth factors for treatment of peripheral neuropathy	10/26/2000
Germany	DE60021360	Angiogenic growth factors for treatment of peripheral neuropathy	5/24/2006
Енгоре	BP1169052	VEGF angiogenic growth factors for treatment of peripheral neuropathy	1/9/2002
France	EP1169052	VEOF angiogenic growth factors for treatment of peripheral neuropathy	7/20/2005
Great Britain	EP1169052	VEGF angiogenic growth factors for treatment of peripheral neuropathy	7/20/2005
Germany	EP1169052	VEGF angiogenic growth factors for treatment of peripheral neuropathy	7/20/2005
Italy	EP1169052	VEGF angiogenic growth factors for treatment of peripheral neuropathy	7/20/2005
Hong Kong	11K1042250	VEGP angiogenic growth factors for treatment of peripheral neuropathy	10/28/2005
PCT	WO0062798	Angiogenic growth factors for treatment of peripheral neuropathy	10/26/2000
PCT	WO2008127251	Reversible inhibition of pyramidal gap junction activity	10/23/2008
Australia	AU772731	AKT compositions for enhancing survival of cells	5/6/2004
Australia	AU6276399	AKT compositions for enhancing survival of cells	4/26/2000
Canada	CA2335391	AKT compositions for enhancing survival of cells	4/13/2000
			4/15/2000

America 4434764.1

8

Country	Publication,	Title	Publication Date,
1	Application, or		Filing Date,
	Patent No.		or Issue Date
Europe	EP1117426	AKT compositions for enhancing survival of cells	7/25/2001
Japan	JP2002528390	AKT compositions for enhancing survival of cells	9/3/2002
PCT	WO0020025	AKT compositions for enhancing survival of cells	4/13/2000
Canada	CA2729633	Tumor-Initiating Cells and methods of use	1/14/2010
PCT	WO2010005532	Tumor-Initiating Cells and methods of use	1/14/2010
PCT	WO2009151618	Methods and compositions for treating Alzheimer's disease	12/17/2009
Canada	CA2608103	Screening assays for compounds regulating DI-1 expression	11/16/2006
PCT	WO2006122090	Cell-based screening assays for compounds that regulate the expression of a tumor marker DJ-1	11/16/2006
Japan	JP2003137811	Function of glycogen synthase kinase in endothelial cell	3/14/2003
PCT	WO2006122090	Cell-based screening assays for compounds that regulate the expression of a tumor marker DJ-1	11/16/2006
PCT	WO2011127291	Compositions and methods for the treatment of neoplasia	10/13/2011

America 4434764.1

**RECORDED: 08/17/2012**